• PhD or postgraduate medical degree with focus in cellular and molecular biology, gene editing, human stem cell biology, hematopoiesis and leukemogenesis
• Experience with gene editing technology, HSC culture, and in vivo models of blood cell disorders is highly desirable
• Excellent analytical, organizational, and communication skills 
  
• English proficiency required
• Ability to work independently and as part of a multidisciplinary team

We are seeking a highly motivated and skilled Postdoctoral Researcher to join our interdisciplinary team dedicated to advancing the understanding of the molecular mechanisms of hematopoiesis, granulopoiesis, and leukemia development. Our research also centers on developing innovative gene therapy approaches for hematopoietic stem cell disorders, with the ultimate goal of clinical translation.

Our division focuses on pre-leukemic bone marrow failure syndromes, supported by the integration of the Severe Chronic Neutropenia International Registry (SCNIR), enabling clinically driven translational research. We employ state-of-the-art experimental models to study inherited diseases such as severe congenital neutropenia and Shwachman-Diamond Syndrome as well as the stepwise process of leukemogenic transformation. Our approach integrates gene editing in human and murine primary hematopoietic and iPSC-derived stem cells, in vivo zebrafish and mouse models, integrative multi-omics analyses (e.g., RNA-seq, ATAC-seq, scRNA-seq, scDNA-seq, targeted NGS, and DigiWest), a broad spectrum of molecular and cellular biology techniques, biochemistry and biophysics, computational drug repurposing, and de novo design of novel protein-based therapeutics. Our work also includes developing gene editing strategies to correct or inactivate mutations associated with severe congenital neutropenia, Shwachman-Diamond Syndrome and leukemia for translational research.

This position offers the opportunity to contribute to the high-impact project „PHOENIX: Promoting Healing and Overcoming ELANE Neutropenia with Ex Vivo CRISPR” with a clear translational goal: bringing gene editing of ELANE-mutated severe congenital neutropenia to clinical application, which is based on a gene editing approach recently published by our group (Nasri M, Ritter M et al., Mol Therapy 2024; Skokowa et al., NEJM 2021). The project is currently funded by the BMBF/SPARK-BIH program.